Belsomra (Suvorexant) Cost in Florida: Prices, Insurance, and Savings in 2026

Suvorexant is the generic name for Belsomra, an FDA-approved dual orexin receptor antagonist (DORA) prescribed for insomnia involving trouble falling asleep, staying asleep, or both. It is not the same drug as lemborexant (Dayvigo), a different DORA, or the older Z-drugs (zolpidem, eszopiclone, zaleplon), though patients often compare all of these when weighing insomnia treatment.

The most useful question for a Florida patient is not "what does Belsomra cost" as a single number, but which payer pathway applies to you, because the pathway determines the price far more than the drug's list price does. Commercial insurance with prior authorization, Florida Medicaid, and cash-pay purchasing are three structurally different routes, and the rules governing each change over time. Suvorexant is FDA-approved (August 2014) and classified as a Schedule IV controlled substance; those facts are stable. Specific dollar amounts for list price, cash price, and copay tiers are not stable, are not documented in the source material available for this article, and should be verified directly with a pharmacy, insurer, or the manufacturer before you rely on them.

What is actually confirmed

Suvorexant received FDA approval in August 2014 for adults with insomnia characterized by difficulty with sleep onset or sleep maintenance, per the FDA-approved prescribing information. It is dispensed in 10 mg and 20 mg tablets, with the label specifying a starting approach at the lowest effective dose taken no more than once nightly, and tablets are meant to be swallowed whole rather than split. Suvorexant is classified as a Schedule IV controlled substance under DEA scheduling, which affects refill limits and how pharmacies handle telehealth prescribing.

No generic version of suvorexant is approved in the United States as of this writing. Because Merck holds patent protection, Belsomra is sold only as a brand-name product, and brand-name pricing (list price, cash price, and insurance copay tier) is exactly the kind of figure that shifts month to month and pharmacy to pharmacy. This article does not publish a specific dollar figure for Belsomra's list price or Florida cash price because no verified primary source for those numbers was available when this draft was prepared; a reader should treat any specific number seen elsewhere as something to confirm at the pharmacy counter or through the insurer, not as a fixed fact.

Florida Medicaid coverage: what needs verification

Whether Florida Medicaid covers suvorexant for primary insomnia, and under what restrictions, is a state formulary decision that can change between plan years and between the state's fee-for-service list and individual managed care organizations. No verified primary source documenting Florida's current Medicaid coverage policy for suvorexant was available for this draft. Patients enrolled in Florida Medicaid or a Florida Medicaid managed care plan should check the current preferred drug list directly with their plan, or ask their prescriber's office to run a coverage check, rather than assume coverage status based on a general description. Generic sedative-hypnotics such as zolpidem are commonly preferred by state formularies because they are older and inexpensive, but whether that applies to a specific Florida plan in 2026 requires direct confirmation.

Commercial insurance: the general pattern

Brand-name drugs with older, cheaper generic alternatives in the same therapeutic category are commonly placed on a higher, non-preferred formulary tier by commercial insurers, and step therapy (trying a generic first) is a common condition before a DORA like suvorexant is approved. This is a general pattern in U.S. pharmacy benefit design, not a Florida-specific rule, and the exact tier, copay amount, and step-therapy requirement depend on the individual plan. A prior authorization request is more likely to succeed when the prescriber documents which generic agents were tried, for how long, and why they failed or caused unacceptable side effects. Beyond this general structure, no verified source in this draft's evidence base documents specific copay ranges or turnaround times for Florida insurers, so those figures are not stated here.

Manufacturer savings card: what is structurally true

Pharmaceutical manufacturers commonly offer copay assistance cards for brand-name drugs that reduce out-of-pocket cost for commercially insured patients. A well-established federal rule, not specific to Merck or to Belsomra, is that these manufacturer copay cards cannot be used by patients covered under federal healthcare programs, including Medicare, Medicaid, TRICARE, or VA benefits. This restriction stems from federal anti-kickback law, which governs remuneration tied to federally reimbursed prescriptions. If a Belsomra savings card is currently offered, its specific discount amount, monthly cap, and enrollment terms are set by the manufacturer and can change; check the manufacturer's current program terms directly rather than relying on a fixed dollar figure.

Compounded suvorexant: legal category, with a quality caveat

Compounding a patient-specific preparation of suvorexant through a licensed 503A pharmacy is generally permitted under federal compounding law, provided the pharmacy holds an active license and there is a valid prescription for an individual patient; suvorexant does not appear on FDA's list of drugs that are restricted from compounding. The distinction between 503A pharmacy compounding and 503B outsourcing facilities matters here: 503A compounding is patient-specific and does not go through the same manufacturing-standard oversight as an FDA-approved product, and 503B outsourcing facilities follow current good manufacturing practice requirements but are typically used for bulk or office-stock supply rather than individual prescriptions. Compounded products are not FDA-approved, meaning they have not been reviewed for safety and efficacy the way Belsomra was. A Florida patient considering a compounded version should confirm the pharmacy's state license status with the Florida Board of Pharmacy and ask whether the pharmacy pursues any voluntary third-party quality accreditation, since compounded product quality can vary by facility. Whether compounded suvorexant is meaningfully cheaper than the brand product in Florida specifically was not confirmed by any source available for this draft and should be checked with the compounding pharmacy directly.

Telehealth prescribing in Florida

Florida law permits prescribing of Schedule III through V controlled substances, which includes suvorexant, following a real-time (synchronous audio-video) evaluation, without requiring a prior in-person visit for the initial prescription. This is a state-level telehealth authorization for controlled substances and is distinct from federal rules governing controlled-substance telehealth generally. Because telehealth and controlled-substance prescribing rules have been in flux at the federal level in recent years, a patient relying on telehealth for an initial suvorexant prescription should confirm with the prescribing platform that its Florida-licensed clinicians are currently authorized to prescribe Schedule IV medications without an in-person visit, since federal flexibilities adopted during the COVID-19 emergency period have been extended and modified multiple times.

How suvorexant compares to older insomnia drugs, and why that matters for cost decisions

Suvorexant works through a different mechanism than the older benzodiazepine receptor agonists (zolpidem, eszopiclone, zaleplon): it blocks orexin receptors rather than enhancing GABA signaling. The FDA has issued a boxed warning regarding complex sleep behaviors, including sleepwalking and sleep-driving, associated with several prescription insomnia medicines, particularly the Z-drug class. This is a real clinical distinction that can justify choosing a costlier DORA over a cheaper generic Z-drug for a specific patient, for example someone with a personal or family history of parasomnias. Whichever drug costs less at a given pharmacy in a given month, the clinical decision about which drug is appropriate should be made with a prescriber based on insomnia subtype, comorbidities, prior treatment response, and risk factors, not on price alone.

The direct answer, in one place

Belsomra (suvorexant) is an FDA-approved, Schedule IV, brand-name dual orexin receptor antagonist for insomnia with no generic equivalent currently on the market in the United States. What a Florida patient actually pays depends on which of three pathways applies (commercial insurance with prior authorization, Florida Medicaid, or cash/discount pay), and the specific dollar amounts within each pathway change over time and by plan, so any fixed price figure should be verified directly with the pharmacy, insurer, or manufacturer at the time of filling rather than assumed from a published estimate.

When to seek urgent care instead of troubleshooting cost

Cost and coverage questions are never worth delaying care for red-flag symptoms. Seek urgent medical attention if a person taking suvorexant experiences sleepwalking, sleep-driving, or other complex behaviors while not fully awake; signs of a severe allergic reaction; new or worsening suicidal thoughts; or profound daytime sedation that impairs safe function (driving, operating machinery). These are safety issues to raise with a prescriber or emergency services regardless of what the medication costs or which pharmacy filled it.

What is established, what is plausible, and what is not established

Established: suvorexant's FDA approval and labeled use, its Schedule IV status, the existence of a boxed warning for complex sleep behaviors across the sleep-medicine class, the general legal framework for 503A/503B compounding, the federal rule excluding Medicare/Medicaid/TRICARE/VA patients from manufacturer copay cards, and Florida's general telehealth authorization for Schedule III-V prescribing.

Plausible but unconfirmed in this draft: that compounded suvorexant is meaningfully cheaper than the brand product in Florida; that a specific manufacturer savings card is currently active and at what discount level; typical commercial insurance copay ranges for Florida plans specifically.

Not established here: any specific Belsomra list price, Florida average cash-pay price, or Florida Medicaid coverage rule for suvorexant, because no verified primary source for these figures was available. Treat any such number found elsewhere as something to confirm directly, not as settled fact.

Verification checklist: stable facts vs. facts that expire

Use this to separate what you can trust as-is from what you must re-check before paying or filing an appeal.

Stable (federal/clinical, unlikely to change quickly)

• Suvorexant/Belsomra FDA approval status and labeled indication, FDA label
• Schedule IV controlled-substance classification
• Boxed warning for complex sleep behaviors across certain insomnia drugs
• 503A vs. 503B compounding framework and legality of compounding suvorexant
• Federal rule barring manufacturer copay cards for federal-program beneficiaries

Date-sensitive (verify before you rely on it, and note the date you checked)

• Whether a generic suvorexant has entered the market
• Current Belsomra list price and cash-pay price at a specific Florida pharmacy
• Florida Medicaid or Florida Medicaid managed care plan's current coverage decision for suvorexant
• Your specific commercial plan's formulary tier, copay amount, and step-therapy requirement for suvorexant
• Whether a Merck (or other) copay savings card is currently active, and its discount terms
• Whether your telehealth platform's Florida-licensed prescribers currently offer initial Schedule IV prescriptions without an in-person visit
• Pricing and licensing status of any specific 503A compounding pharmacy you are considering

Before filling a prescription or filing an insurance appeal, confirm each date-sensitive item directly with the source (pharmacy, insurer, prescriber's office, or manufacturer program) and record the date you confirmed it.